IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the skin, bacterial DNA was analyzed from swabs co...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of investigative dermatology Ročník 140; číslo 1; s. 191
Hlavní autori: Callewaert, Chris, Nakatsuji, Teruaki, Knight, Rob, Kosciolek, Tomasz, Vrbanac, Alison, Kotol, Paul, Ardeleanu, Marius, Hultsch, Thomas, Guttman-Yassky, Emma, Bissonnette, Robert, Silverberg, Jonathan I, Krueger, James, Menter, Alan, Graham, Neil M H, Pirozzi, Gianluca, Hamilton, Jennifer D, Gallo, Richard L
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.01.2020
Predmet:
Antibodies, Monoclonal, Humanized - therapeutic use
Cytokines - metabolism
Dermatitis, Atopic - drug therapy
Disease Progression
Double-Blind Method
Female
Follow-Up Studies
Humans
Immunotherapy - methods
Male
Placebos
Receptors, Interleukin-4 - antagonists & inhibitors
RNA, Ribosomal, 16S - genetics
Skin - drug effects
Skin - microbiology
Staphylococcal Infections - drug therapy
Staphylococcus aureus - physiology
Th2 Cells - immunology
ISSN:1523-1747, 1523-1747
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the skin, bacterial DNA was analyzed from swabs collected from lesional and nonlesional skin in a double-blind, placebo-controlled study of 54 patients with moderate to severe AD randomized (1:1) and treated with either dupilumab (200 mg weekly) or placebo for 16 weeks. Microbial diversity and relative abundance of Staphylococcus were assessed by DNA sequencing of 16S ribosomal RNA, and absolute S. aureus abundance was measured by quantitative PCR. Before treatment, lesional skin had lower microbial diversity and higher overall abundance of S. aureus than nonlesional skin. During dupilumab treatment, microbial diversity increased and the abundance of S. aureus decreased. Pronounced changes were seen in nonlesional and lesional skin. Decreased S. aureus abundance during dupilumab treatment correlated with clinical improvement of AD and biomarkers of type 2 immunity. We conclude that clinical improvement of AD that is mediated by interleukin-4 receptor α inhibition and the subsequent suppression of type 2 inflammation is correlated with increased microbial diversity and reduced abundance of S. aureus.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:1523-1747
1523-1747
DOI:10.1016/j.jid.2019.05.024